Navigating the UK medical device market can be a complex journey. For biotech and SME companies, understanding the regulatory landscape is crucial to efficiently and safely bringing innovative products to patients. As someone deeply involved in this field, I know that medical device entry consulting is not just about ticking boxes; it’s about creating a strategic pathway that accelerates market access while ensuring compliance and patient safety.

Navigating the complex regulatory compliance landscape in the UK is a critical challenge for biotech and SME companies in the medical device and pharmaceutical sectors. As someone deeply involved in this field, I understand how essential it is to have a trusted partner who can guide you through the intricacies of regulations, ensuring your innovations reach patients safely and efficiently. Regulatory affairs play a pivotal role in this process, acting as the bridge between yo

The convergence of artificial intelligence and pharmaceutical innovation is no longer a distant vision; it’s today’s reality. With a projected market size of $116.49 billion by the end of 2025 and a 27% compound annual growth rate (CAGR), AI in pharma is reshaping everything from drug discovery to diagnostics.

In 2025, manufacturers of AI-powered medical devices face a new regulatory reality. The European Union has introduced the Artificial Intelligence Act (AIA). If your device falls under the Medical Device Regulation (MDR) or the In Vitro Diagnostic Regulation (IVDR), the AIA is mandatory. It’s now a core part of your compliance strategy.